drugset
drugset / Trial / NCT05020483

FEIBA to Optimize Postcardiopulmonary Bypass Hemostasis in Pediatric Cardiac Patients

NCT05020483 ↗

Phase 2 Withdrawn Mayo Clinic
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this research is to understand if the medication called FEIBA helps to stop bleeding and decrease transfusion of blood products to small children operated on the heart.

Timeline

Start
2021-10
Primary completion
2023-12
Completion
2023-12

Outcome

Outcome not reported

Stopped: “Patient population changed and no subjects eligible for the study.”

Drugs

EvaluationDrugModalityDoseRoute
Subject activated prothrombin complex concentrate (aPCC) FEIBA Protein / enzyme biologic 5 mg/kg Intravenous

Indications

heart disorder